company background image
AUPH

Aurinia Pharmaceuticals NasdaqGM:AUPH Stock Report

Last Price

US$4.95

Market Cap

US$703.4m

7D

6.5%

1Y

-73.7%

Updated

29 Nov, 2022

Data

Company Financials +
AUPH fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AUPH Stock Overview

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally.

Aurinia Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aurinia Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.95
52 Week HighUS$24.45
52 Week LowUS$4.49
Beta0.92
1 Month Change-38.28%
3 Month Change-32.75%
1 Year Change-73.73%
3 Year Change-37.97%
5 Year Change-1.00%
Change since IPO141.46%

Recent News & Updates

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Nov 04
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Recent updates

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Nov 04
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Analysts Just Slashed Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) EPS Numbers

Mar 10
Analysts Just Slashed Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) EPS Numbers

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 03
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Shareholder Returns

AUPHUS BiotechsUS Market
7D6.5%-1.0%-0.9%
1Y-73.7%-15.2%-18.9%

Return vs Industry: AUPH underperformed the US Biotechs industry which returned -16.1% over the past year.

Return vs Market: AUPH underperformed the US Market which returned -20.5% over the past year.

Price Volatility

Is AUPH's price volatile compared to industry and market?
AUPH volatility
AUPH Average Weekly Movement12.5%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: AUPH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: AUPH's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a300Peter Greenleafhttps://www.auriniapharma.com

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd.

Aurinia Pharmaceuticals Inc. Fundamentals Summary

How do Aurinia Pharmaceuticals's earnings and revenue compare to its market cap?
AUPH fundamental statistics
Market CapUS$703.44m
Earnings (TTM)-US$115.46m
Revenue (TTM)US$129.00m

5.5x

P/S Ratio

-6.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AUPH income statement (TTM)
RevenueUS$129.00m
Cost of RevenueUS$51.05m
Gross ProfitUS$77.95m
Other ExpensesUS$193.41m
Earnings-US$115.46m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.81
Gross Margin60.43%
Net Profit Margin-89.50%
Debt/Equity Ratio0%

How did AUPH perform over the long term?

See historical performance and comparison